Tesamorelin (TESA)

FDA-approved GHRH analog for HIV-associated lipodystrophy. Reduces visceral adipose tissue while maintaining metabolic parameters.

Key Data

Research Status

FDA approved

Half-Life

26-38 minutes

Administration

Subcutaneous injection

Typical Dosage

2 mg daily

Mechanism of Action

Synthetic GHRH analog with trans-3-hexenoic acid modification, stimulates natural GH release.

Reported Benefits

• Visceral fat reduction
• FDA approved
• Improved body composition
• Metabolically favorable

All information is presented for Research Use Only (RUO). Not medical advice.